CL2021003580A1 - Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso - Google Patents

Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso

Info

Publication number
CL2021003580A1
CL2021003580A1 CL2021003580A CL2021003580A CL2021003580A1 CL 2021003580 A1 CL2021003580 A1 CL 2021003580A1 CL 2021003580 A CL2021003580 A CL 2021003580A CL 2021003580 A CL2021003580 A CL 2021003580A CL 2021003580 A1 CL2021003580 A1 CL 2021003580A1
Authority
CL
Chile
Prior art keywords
compounds
activation protein
protein ligand
fibroblast activation
fibroblast
Prior art date
Application number
CL2021003580A
Other languages
English (en)
Spanish (es)
Inventor
Frank Osterkamp
Dirk Zboralski
Eberhard Schneider
Christian Haase
Matthias Paschke
Aileen Höhne
Jan Ungewiss
Christiane Smerling
Ulrich Reineke
Anne Bredenbeck
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of CL2021003580A1 publication Critical patent/CL2021003580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2021003580A 2019-07-08 2021-12-30 Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso CL2021003580A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19198813 2019-09-20

Publications (1)

Publication Number Publication Date
CL2021003580A1 true CL2021003580A1 (es) 2022-08-05

Family

ID=71409439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003580A CL2021003580A1 (es) 2019-07-08 2021-12-30 Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso

Country Status (20)

Country Link
US (2) US12427210B2 (https=)
EP (2) EP3997103B9 (https=)
JP (3) JP7608425B2 (https=)
KR (1) KR20220032079A (https=)
CN (3) CN118406106A (https=)
AU (1) AU2020310538B2 (https=)
BR (1) BR112022000122A2 (https=)
CA (1) CA3145340A1 (https=)
CL (1) CL2021003580A1 (https=)
DK (1) DK3997103T3 (https=)
ES (1) ES3012534T3 (https=)
FI (1) FI3997103T3 (https=)
HU (1) HUE070009T2 (https=)
IL (2) IL320543A (https=)
LT (1) LT3997103T (https=)
MX (1) MX2022000252A (https=)
PL (1) PL3997103T3 (https=)
RS (1) RS66480B9 (https=)
SI (1) SI3997103T1 (https=)
WO (1) WO2021005125A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289673B2 (en) * 2019-07-08 2026-04-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
EP4251639A1 (en) * 2020-11-30 2023-10-04 Rayzebio, Inc. Radiopharmaceutical conjugate compositions and uses thereof
US20240139350A1 (en) * 2021-02-01 2024-05-02 Five Eleven Pharma, Inc Radioactively labeled ligand for fibroblast activation protein-alpha imaging agent and preparation method therefor
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
NZ803235A (en) 2021-02-10 2026-01-30 Yantai Lannacheng Biotechnology Co Ltd Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
EP4311557A1 (en) * 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates
JP2025530229A (ja) * 2022-09-07 2025-09-11 ３ベー ファーマシューティカルズ ゲーエムベーハー 前立腺特異的膜抗原（ｐｓｍａ）リガンドおよびその使用
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
WO2024198838A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
KR20260009883A (ko) 2023-05-24 2026-01-20 베이징 창핑 래보러토리 신규 삼관능 화합물 및 이의 용도
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
CN121752300A (zh) 2023-08-31 2026-03-27 荷兰拉德堡德大学学术医学中心 子宫内膜异位症示踪剂
WO2025063849A2 (en) 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
TW202532108A (zh) 2024-02-01 2025-08-16 瑞士商諾華公司 治療癌症的方法
CN121045338A (zh) * 2025-11-05 2025-12-02 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304206A1 (en) 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
EP1943257A2 (en) 2005-05-19 2008-07-16 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CN106794264B (zh) 2014-06-10 2021-03-23 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
EP3405476B1 (en) 2016-01-20 2022-05-18 Polypeptide Laboratories Holding (PPL) AB METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
WO2017211809A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CN106046121B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
CN105949282B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
IL289673B2 (en) 2019-07-08 2026-04-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
KR20230129261A (ko) 2021-01-07 2023-09-07 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Also Published As

Publication number Publication date
SI3997103T1 (sl) 2025-04-30
HUE070009T2 (hu) 2025-05-28
IL289675A (en) 2022-03-01
EP3997103B1 (en) 2024-11-20
RS66480B9 (sr) 2025-05-30
AU2020310538A1 (en) 2022-01-27
CN118406106A (zh) 2024-07-30
FI3997103T3 (fi) 2025-02-03
BR112022000122A2 (pt) 2022-04-26
ES3012534T3 (en) 2025-04-09
US20260061086A1 (en) 2026-03-05
JP7608425B2 (ja) 2025-01-06
JP2022541753A (ja) 2022-09-27
JP7783396B2 (ja) 2025-12-09
PL3997103T3 (pl) 2025-03-24
EP4517326A3 (en) 2025-05-28
JP2025038131A (ja) 2025-03-18
DK3997103T3 (da) 2024-12-02
EP4517326A2 (en) 2025-03-05
RS66480B1 (sr) 2025-03-31
WO2021005125A1 (en) 2021-01-14
IL320543A (en) 2025-06-01
CN114341159B (zh) 2024-04-26
IL289675B1 (en) 2025-09-01
US20220273831A1 (en) 2022-09-01
US12427210B2 (en) 2025-09-30
JP2026035703A (ja) 2026-03-04
IL289675B2 (en) 2026-01-01
CN114341159A (zh) 2022-04-12
CA3145340A1 (en) 2021-01-14
AU2020310538B2 (en) 2026-04-09
MX2022000252A (es) 2022-02-21
EP3997103A1 (en) 2022-05-18
CN118388588A (zh) 2024-07-26
LT3997103T (lt) 2025-02-25
KR20220032079A (ko) 2022-03-15
EP3997103B9 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
CL2021003580A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
IL289673A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
CO2020001983A2 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2020000174S1 (es) Automóvil.
CL2019001554S1 (es) Automóvil.
CL2021001627A1 (es) Molécula bifuncional anti-pd-1/sirpa
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
CL2019002232S1 (es) Automóvil.
CL2020001201S1 (es) Automóvil.
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
CO2019013718A2 (es) Anticuerpos anti-trkb
EP3947466A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES
EP3916436A4 (en) DIFFUSION PLATE
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
AU201815763S (en) Quick connection coupler